Kuchyne na miru

Emerging Pharma Leaders 2014

Aug 01, 2014
By Pharmaceutical Executive Editors

This year's class of 15 young executives is deeply of the moment, with assignments that include advancing therapies against hepatitis C, building new cell-based platforms in regenerative medicine, creating new businesses beyond a protected home base, restructuring the supply chain to accommodate a new generation of complex biologics, and transforming raw data into "news I can use" analytics. The emotional viscera that binds all is a commitment to the patient. Despite those legions of lawyers, accountants, bankers, and regulators—none of whom made the list this year—pharma remains at heart a people business.

And the Leaders Are...

(In alphabetical order)

Joerg Ahlgrimm, VP of Operations, Baxter BioScience

Jenise Doutsas, Global Strategic Lead, Fertility, Ferring Pharmaceuticals

Brian Goff, Global Franchise Head, Hemophilia, Baxter Healthcare

Ian Harris, Senior Director and Platform Leader, Cell Therapy, Janssen Research & Development

Susanne Heinzinger, Executive Director of Product Strategy and Alliance Management, Achillion Pharmaceuticals

Michael Injaychock, Director, Marketing Innovation, Research and Commercial Analytics, Eli Lilly & Co.

Sachin Jain, Chief Medical Information and Innovation Officer, Merck & Co.

Arnaud Lesegretain, Vice President, Global Brand Development, Eli Lilly & Co.

Tom McDonnell, Vice President, Product Strategy Lead—Neuroscience, Shire Pharmaceuticals

Jamey Millar, VP Oncology Business Unit Head, GlaxoSmithKline

António Portela, CEO, Bial

Alexsey Repik, Founder and Chairman of the Board, R-Pharm

Monica Tellado, VP, US commercial operations. Gilead Sciences

Hayden Thomas, VP, formulation development, Vertex Pharmaceuticals

Jocelyn Trokenheim, Head of Global Business Development Office and Strategy, Takeda Pharmaceuticals



lorem ipsum